
  
    
      
        
        As_IN cells_NNS specialize_VBP during_IN development_NN they_PRP pass_VBP through_IN different_JJ levels_NNS of_IN
        differentiation_NN ,_, from_IN the_DT earliest_JJS stem_NN cells_NNS through_IN to_TO the_DT highly_RB specialized_JJ types_NNS that_WDT
        make_VBP up_RP the_DT body_NN 's_POS organs_NNS ._. Hence_RB ,_, a_DT number_NN of_IN different_JJ tissues_NNS may_MD derive_VB from_IN common_JJ
        precursors_NNS ._. For_IN example_NN ,_, muscle_NN ,_, fat_JJ ,_, cartilage_NN ,_, and_CC bone_NN are_VBP all_DT derived_VBN from_IN a_DT group_NN of_IN
        mesenchymal_NN precursor_NN cells_NNS that_WDT originate_VB in_IN the_DT paraxial_NN mesoderm_NN ._. So_RB pluripotent_NN (_( i_NNP ._. e_SYM ._. ,_,
        able_JJ to_TO differentiate_VB into_IN any_DT cell_NN type_NN )_) human_JJ embryonic_JJ stems_VBZ cells_NNS are_VBP potentially_RB a_DT
        starting_NN point_NN for_IN the_DT regeneration_NN of_IN all_DT types_NNS of_IN diseased_JJ or_CC damaged_JJ organs_NNS (_( and_CC already_RB
        researchers_NNS have_VBP shown_VBN that_IN it_PRP is_VBZ possible_JJ to_TO stimulate_VB human_JJ embryonic_JJ stem_NN cells_NNS to_TO
        differentiate_VB into_IN specific_JJ cell_NN types_NNS such_JJ as_IN neural_NN or_CC hematopoietic_JJ cells_NNS )_) ._. The_DT
        isolation_NN of_IN intermediate_JJ multipotent_NN stem_NN cells_NNS (_( which_WDT can_MD differentiate_VB into_IN a_DT limited_JJ
        number_NN of_IN cell_NN types_NNS )_) may_MD also_RB be_VB valuable_JJ ._. For_IN example_NN ,_, the_DT production_NN of_IN an_DT unlimited_JJ
        supply_NN of_IN mesenchymal_NN precursors_NNS would_MD be_VB very_RB useful_JJ ,_, not_RB only_RB for_IN the_DT understanding_NN of_IN
        how_WRB cells_NNS differentiate_VB ,_, but_CC also_RB for_IN eventual_JJ practical_JJ application_NN ._.
        In_IN this_DT month_NN 's_POS 
        PLoS_NNP Medicine_NNP ,_, Lorenz_NNP Studer_NNP and_CC colleagues_NNS from_IN the_DT Sloan-_NNP Kettering_NNP
        Institute_NNP in_IN New_NNP York_NNP describe_VB a_DT protocol_NN for_IN deriving_VBG mesenchymal_NN precursors_NNS ,_, which_WDT they_PRP
        then_RB show_VBP are_VBP capable_JJ of_IN differentiating_VBG into_IN specialized_JJ cell_NN types_NNS ._.
        They_PRP used_VBD two_CD undifferentiated_JJ stem_NN cell_NN lines—from_NN the_DT 22_CD lines_NNS that_WDT were_VBD approved_VBN in_IN
        2001_CD by_IN President_NNP Bush_NNP for_IN use_NN in_IN federally_RB funded_VBN research_NN in_IN the_DT United_NNP States_NNPS ._. The_DT
        specifications_NNS for_IN approval_NN for_IN these_DT lines_NNS are_VBP clear—see_NN the_DT guidelines_NNS at_IN
        http_NN :_: /_NN /_NN stemcells_NNS ._. nih_NN ._. gov_NN /_NN research_NN /_NN registry_NN /_NN eligibilityCriteria_NN ._. asp_NN ._. The_DT number_NN of_IN human_JJ
        embryonic_JJ stem_NN cell_NN lines_NNS available_JJ for_IN researchers_NNS are_VBP strictly_RB limited_JJ ,_, making_VBG it_PRP
        necessary_JJ to_TO develop_VB protocols_NNS that_WDT expand_VBP these_DT cells_NNS along_IN various_JJ lineages_NNS ._.
        In_IN order_NN to_TO differentiate_VB the_DT cells_NNS into_IN mesenchymal_NN precursors_NNS ,_, the_DT stem_NN cell_NN lines_NNS
        were_VBD cocultured_JJ with_IN mouse_NN feeder_NN cells_NNS to_TO produce_VB five_CD different_JJ polyclonal_NN lines_NNS ._. The_DT
        authors_NNS then_RB cultured_JJ these_DT polyclonal_NN precursors_NNS with_IN appropriate_JJ tissue-specific_JJ
        stimulation_NN in_IN attempt_NN to_TO produce_VB fat_JJ ,_, bone_NN ,_, cartilage_NN ,_, or_CC muscle_NN cells_NNS ._. The_DT evidence_NN that_IN
        the_DT authors_NNS provide_VBP for_IN these_DT cells_NNS being_VBG differentiated_JJ includes_VBZ analysis_NN of_IN gene_NN
        expression_NN ,_, surface_NN antigens_NNS ,_, and_CC immunocytochemistry_NN typical_JJ of_IN the_DT mature_VBP tissues_NNS ._. For_IN
        example_NN ,_, the_DT authors_NNS were_VBD able_JJ to_TO show_VB the_DT presence_NN of_IN fat_JJ granules_NNS in_IN adipocytes_NNS ,_, calcium_NN
        in_IN the_DT matrix_NN of_IN osteogenic_JJ cells_NNS ,_, and_CC collagen_NN in_IN chondrocytes_NNS ._. It_PRP was_VBD harder_RBR to_TO produce_VB
        muscle_NN cells_NNS ,_, but_CC even_RB these_DT types_NNS of_IN cells_NNS could_MD eventually_RB be_VB induced_VBN by_IN specific_JJ culture_NN
        conditions_NNS ._.
        What_WP are_VBP the_DT possible_JJ concerns_NNS about_IN these_DT types_NNS of_IN studies_NNS ?_. One_CD obvious_JJ one_CD is_VBZ the_DT
        potential_NN for_IN residual_JJ undifferentiated_JJ cells_NNS to_TO turn_VB into_IN tumors_NNS ,_, but_CC the_DT authors_NNS tested_VBD
        the_DT differentiated_JJ cell_NN cultures_NNS for_IN cell_NN surface_NN markers_NNS characteristic_NN of_IN
        undifferentiated_JJ cells_NNS and_CC found_VBD no_DT evidence_NN of_IN them_PRP ._. Another_DT worry_VBP for_IN the_DT use_NN of_IN these_DT
        cells_NNS directly_RB in_IN humans_NNS is_VBZ the_DT need_NN ,_, at_IN least_JJS at_IN the_DT beginning_NN ,_, to_TO culture_NN the_DT cells_NNS with_IN
        mouse_NN feeder_NN cells—obviously_RB no_DT human_JJ treatment_NN could_MD contain_VB cells_NNS contaminated_VBN with_IN mouse_NN
        cells_NNS ._. Further_RB development_NN of_IN protocols_NNS will_MD be_VB needed_VBN to_TO address_VB this_DT issue_NN ._. However_RB ,_, as_IN
        the_DT authors_NNS comment_NN ,_, “ the_DT high_JJ purity_NN ,_, unlimited_JJ availability_NN ,_, and_CC multipotentiality_NN of_IN
        hESMPCs_NNS [_NN human_JJ embryonic_JJ stem_NN cell–derived_JJ mesenchymal_NN precursor_NN cells_NNS ]_NN will_MD provide_VB the_DT
        basis_NN for_IN future_JJ therapeutic_JJ efforts_NNS using_VBG these_DT cells_NNS in_IN preclinical_JJ animal_NN models_NNS of_IN
        disease_NN ._.” In_IN addition_NN ,_, the_DT techniques_NNS described_VBD here_RB will_MD provide_VB a_DT very_RB useful_JJ resource_NN
        for_IN studying_VBG mesenchymal_NN cell_NN development_NN ._.
      
    
  
